Arcus Biosciences
BiotechUnited States
4
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
6
Indications↗
Distinct diseases across all programs
37
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
4 drugs in development
Phase 31
Phase 14
By Therapeutic Area
top 1
Oncology
4100%
R&D Momentum
48/100
Pipeline Velocity
15/100
Trial Completion Rate
100/100
Pipeline Concentration
100/100
Pipeline Freshness
71/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
Activity
Recent Activity
Last 14 days
Jul 7, 2026
Recruiting
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Jul 3, 2026
Active, not recruiting
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
Jul 3, 2026
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors
Jul 3, 2026
Active, not recruiting
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
Jul 3, 2026
Active, not recruiting
A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)
Jul 2, 2026
Active, not recruiting
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Jul 2, 2026
Active, not recruiting
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
4 more events
Feb 3, 2026TrialMetabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)
May 2, 2025TrialDrug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
Oct 16, 2023TrialA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers
Aug 21, 2023TrialA Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Oncology
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)